Last reviewed · How we verify
NCT04346264
CoVid-19 - Infection and Antibody Formation in the Viennese Population
trial testing NO intervention planned due to the observational study design only a diagnostic testing in Virus Diseases in 12,419 participants. Completed in 27 May 2020.
27 May 2020
Quick facts
| Lead sponsor | Ludwig Boltzmann Institute for Lung Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 12,419 |
| Start date | 27 April 2020 |
| Primary completion | 27 May 2020 |
| Estimated completion | 27 May 2020 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- NO intervention planned due to the observational study design only a diagnostic testing
Conditions studied
- Virus Diseases — all drugs for Virus Diseases →
- COVID-19 — all drugs for COVID-19 →
Sponsor
Ludwig Boltzmann Institute for Lung Health
Who can join
Adults 6 to 85, any sex, with Virus Diseases or COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Summary of the study Study population: A representative sample of the Viennese population stratified by age and gender (data from the Vienna Health Study LEAD) Potential output and analysis: * Extent of age-specific infection and antibody formation * Cumulative incidence of infection * Rate of asymptomatic infection * Relationship with socioeconomics, lifestyle and risk factors (comorbidities) Study design: Prospective, longitudinal, stratified by age and gender Duration of study: Initial testing as soon as possible and repeat based on monitoring of the pandemic curve (probably after 2-3 months) Information to be obtained from participants: * serum samples for information on SARS-CoV2 infection and antibody formation * data on clinical symptoms
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.
Breyer MK, Breyer-Kohansal R, Hartl S, Kundi M, et al · · 2021 · cited 13× · PMID 33980950 · DOI 10.1038/s41598-021-89711-5
Verify or expand the search:
- PubMed search for NCT04346264
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Virus Diseases
Currently open trials in the same condition.
- NCT05797246 — Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) · Phase 2 · active not recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
Other Ludwig Boltzmann Institute for Lung Health trials
Trials by the same sponsor.
- NCT06522334 — Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria · recruiting
- NCT06522347 — Mycobacteria Registry Study: Prospective Observational Study in Austria · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04346264 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ludwig Boltzmann Institute for Lung Health
- Last refreshed: 4 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04346264.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing